Article Details

Lyell Immunopharma Presents First in Human Trial Design of LYL797 at ESMO 2022

Retrieved on: 2022-09-12 07:01:36

Tags for this article:

Click the tags to see associated articles and topics

Lyell Immunopharma Presents First in Human Trial Design of LYL797 at ESMO 2022. View article details on hiswai:

Excerpt

“These reprogramming technologies are designed to overcome primary ... and epigenetic reprogramming technology platforms, Gen-R™ and Epi-R™, ...

Article found on: www.globenewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up